TABLE 1

Patient Characteristics

Characteristic	Center 1	Center 2	Center 3	P
No. of patients	13	14	5
Age (y)	69 (52–88)	65 (47–75)^*	69 (64–77)	0.05^*
Length (cm)	176 (165–185)	184 (164–194)^*	172 (164–177)	0.03^*
Weight (kg)	83 (66–122)	88 (65–125)	90 (68–106)	0.88
Gleason score	8 (7–10)	8 (5–10)	7.5 (6–9)	0.31
PSA (ng/mL)	4.9 (0.5–1,298)^†	103 (11–1,602)	107 (15–436)	0.001^†
Lesion (n)				0.06^‡
Bone	36	62	21
Lymph node	6	13	9
Soft tissue	2	0	0
Location (n)				0.99^‡
Skull	1	2	0
Cervical vertebrae	2	5	2
Thoracic vertebrae	4	7	2
Lumbar vertebrae	5	8	2
Sacral vertebrae	4	9	2
Pelvis	6	7	2
Ribs/sternum/clavicles	10	17	7
Extremities	4	7	2
Pelvic	2	6	6
Upper abdominal	1	2	2
Thoracic	3	3	0
Neck	2	2	2
Scanner type	GE 690 or GE710	Philips Gemini TF 64	Philips Ingenuity TF 128
Uptake time (min)
Test	46 (36–53)	45 (45–47)^§	60 (42–60)	0.06
Retest	47 (38–59)	45 (44–48)^§	60 (57–67)^‖	0.00^‖
Injected activity (MBq)
Test	306 (241–348)	194 (152–216)^*	309 (234–319)	0.00^*
Retest	323 (298–355)	193 (186–215)^*	295 (251–333)	0.00^*
Residual dose (MBq)
Test	16.4 (5.85–30.7)	36.5 (26.0–62.5)^*	16.1 (14.4–31.8)	0.00^*
Retest	15.7 (6.68–28.7)	35.9 (18.4–53.5)^*	20.5 (14.1–24.8)	0.00^*

↵* Significant difference between sites (1-way ANOVA).
↵† Prostate-specific antigen (PSA) levels were significantly lower for Center 1 (Kruskal–Wallis test).
↵‡ χ² test.
↵§ Variability was significantly different from other 2 sites (Levene test).
↵‖ Uptake time was significantly longer for Center 3 (Kruskal–Wallis test).
Data are median, with range given in parentheses.